

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: John W. Benbow, et al. :

APPLICATION NO.: To be assigned : Examiner: To be assigned

FILING DATE: Concurrently herewith : Group Art Unit: To be assigned

TITLE: SUBSTITUTED 4- :
AMINO[1,2,4]TRIAZOLO[4,3-
a]QUINOXALINES

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: MARCH 22, 2006



Carl J. Goddard
Attorney for Applicant(s)
Reg. No. 39,203

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 441-4902

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>								ATTY. DOCKET NO. PC25078A				SERIAL NO. To be assigned							
								APPLICANT John W. Benbow, et al.											
								FILING DATE Concurrently herewith				GROUP To be assigned							
U.S. PATENT DOCUMENTS																			
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE						
	US	0	1	0	3	1	8	5	08/01/02	Sanner et al.	A61K	31/55							
FOREIGN PATENT DOCUMENTS																			
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION						
													YES	NO					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																			
			Singh, P. et al., Indian Journal of Chemistry, Vol. 35B, pp. 929-934, September 1996, "Fujita-Ban and Hansch analyses of A ₁ - and A ₂ -adenosine receptor binding affinities of some 4-amino[1,2,4]triazolo[4,3- α]quinoxalines."																
			Sarges, R. et al., J. Med. Chem., Vol. 33, pp. 2240-2254, 1990, "4-Amino[1,2,4]triazolo[4,3- α]quinoxalines. A Novel Class of Potent Adenosine Receptor Antagonists and Potential Rapid-Onset Antidepressants."																
			Adenot, M. et al., Eur J Med Chem, Vol. 32, pp. 493-504, 1997, "Interest of cluster significance analysis in structure-affinity relationships for non-xanthine heterocyclic antagonists of adenosine."																
			Colotta, V. et al., Arch. Pharm. Pharm. Med. Chem., Vol. 332, pp. 39-41, 1991, "4-Amino-6-benzylamino-1,2-dihydro-2-phenyl-1,2,4-triazolo[4,3- α]quinoxalin-1-one: A New A _{2A} Adenosine Receptor Antagonist with High Selectivity versus A ₁ Receptors."																
			Colotta, V. et al., J. Med. Chem., Vol. 43, pp. 1158-1164, 2000, "1,2,4-Triazolo[4,3- α]quinoxalin-1-one: A Versatile Tool for the Synthesis of Potent and Selective Adenosine Receptor Antagonists."																
<div style="display: flex; justify-content: space-between;"> EXAMINER DATE CONSIDERED </div>																			
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>																			

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

EXPRESS MAIL NO. EV123872423US

INFORMATION DISCLOSURE CITATION LIST.DOT, 9/99